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Abstract
Background. The randomized phase II INTELLANCE-2/EORTC_1410 trial on EGFR-amplified recurrent glioblastomas 
showed a trend towards improved overall survival when patients were treated with depatux-m plus temozolomide 
compared with the control arm of alkylating chemotherapy only. We here performed translational research on ma-
terial derived from this clinical trial to identify patients that benefit from this treatment.
Methods. Targeted DNA-sequencing and whole transcriptome analysis was performed on clinical trial samples. 
High-throughput, high-content imaging analysis was done to understand the molecular mechanism underlying 
the survival benefit.
Results. We first define the tumor genomic landscape in this well-annotated patient population. We find that tumors 
harboring EGFR single-nucleotide variations (SNVs) have improved outcome in the depatux-m + TMZ combination 
arm. Such SNVs are common to the extracellular domain of the receptor and functionally result in a receptor that 
is hypersensitive to low-affinity EGFR ligands. These hypersensitizing SNVs and the ligand-independent EGFRvIII 
variant are inversely correlated, indicating two distinct modes of evolution to increase EGFR signaling in glio-
blastomas. Ligand hypersensitivity can explain the therapeutic efficacy of depatux-m as increased ligand-induced 
activation will result in increased exposure of the epitope to the antibody–drug conjugate. We also identified tu-
mors harboring mutations sensitive to “classical” EGFR tyrosine-kinase inhibitors, providing a potential alternative 
treatment strategy.
Conclusions. These data can help guide treatment for recurrent glioblastoma patients and increase our under-
standing into the molecular mechanisms underlying EGFR signaling in these tumors.
Key Points
 • SNVs in EGFR are correlated with improved survival to depatux-m + temozolomide.
 • Common SNVs in EGFR increase sensitivity of the receptor to its ligands.
 • Some gliomas harbor EGFR tyrosine-kinase inhibitor sensitive mutations.
EGFR mutations are associated with response to 
depatux-m in combination with temozolomide and 
result in a receptor that is hypersensitive to ligand
  
 2 Hoogstrate et al. EGFR receptor hypersensitivity and response to depatux-m
The epidermal growth factor receptor (EGFR) gene is amp-
lified in approximately half of all glioblastoma patients.1,2 
Unfortunately, and despite EGFR being a driver mutation in 
glioblastomas, pharmacological inhibition of the receptor 
has not been demonstrated to affect patient survival or 
tumor growth.3–5 Depatuxizumab mafodotin (depatux-m, 
ABT414) is an antibody–drug conjugate that consists of an 
antibody directed against EGFR,6,7 conjugated to a toxin 
(monomethyl auristatin F) that blocks microtubule polymer-
ization. The antibody is specific for tumors that overexpress 
EGFR and preferentially binds to the active conformation of 
the receptor and the constitutively active variant, EGFRvIII.6–8 
Depatux-m therefore should specifically target glioblastoma 
cells by using the high expression level of EGFR. Phase 
I clinical trials have tested the drug for safety and toxicity 
and showed some encouraging responses especially in re-
current glioblastoma patients with EGFR amplification.9–11
INTELLANCE-2/EORTC_1410 was a randomized phase 
II trial on EGFR-amplified recurrent glioblastomas that 
showed a trend towards improved overall survival (HR 0.71, 
95% CI [0.50, 1.02], P = .06 in the primary analysis, HR 0.66, 
95% CI [0.48, 0.93], P  =  .024 in follow-up analysis) when 
patients were treated with depatux-m and temozolomide 
(TMZ) compared with the control arm of alkylating che-
motherapy only. In the present study, we aimed to identify 
patients that benefit from this combination and to under-
stand the mechanism of increased sensitivity.
Methods
Patient Samples
Recurrent GBM patients were considered eligible for the 
INTELLANCE-2/EORTC_1410 trial (NCT02343406) if they 
had been diagnosed with a histologically confirmed, EGFR-
amplified glioblastoma at first occurrence. Amplification of 
the EGFR locus was centrally determined using FISH in one 
of the three laboratories (Histogenex, Antwerp Belgium, 
Mosaic, Lake Forest California, Peter MacCallum Cancer 
Institute Melbourne, Australia) using the Vysis EGFR CDx 
Assay (Abbott Molecular, Des Plaines, IL; not on market).12 
A tumor was considered EGFR-amplified when the EGFR/
centromere chromosome 7 (CEP7) ratio was ≥2 in ≥15% 
recorded nuclei, with 50 nuclei/tumor analyzed. Tumors 
with polysomy for chromosome 7 (CEP7 copy number > 
3)  but without focal amplification of the EGFR gene in ≥ 
15% nuclei were considered to be EGFR-nonamplified and 
not included. Two hundred sixty patients were random-
ized in the trial to receive either i) TMZ or, if progressing 
within 16 weeks of day 1 of the last temozolomide cycle, 
CCNU (n = 26 and 60, respectively); ii) depatux-m (n = 86); 
or iii) TMZ plus depatux-m (n = 88). For this analysis, the 
database was locked on January 12, 2018 (longer term 
follow-up data). MGMT promoter methylation status 
data were previously described and determined using a 
methylation-specific PCR.13 All patients gave written in-
formed consent for trial participation, pathology review, 
and molecular testing.
Sequencing
Material, either tissue sections or tissue blocks, were cen-
trally collected at Erasmus MC. Evaluation of the area 
with highest tumor content was done by the pathologist 
(J.M.K.) on a hematoxylin and eosin stained section. One 
to twenty 5μ sections were then sent to Almac Diagnostics 
(Craigavon, UK) for macro-dissection, DNA and RNA ex-
traction, and sequencing. DNA/RNA extraction was per-
formed using the Allprep DNA/RNA FFPE kit (Qiagen, Venlo, 
The Netherlands). Sequencing was done on the Trusight 
Tumor 170 panel (Illumina, Eindhoven, The Netherlands) 
which uses a combination of DNA and RNA sequencing to 
interrogate SNVs in ~150 genes, amplification of 59 genes, 
and fusion and splice-variant expression in 55 genes. SNV, 
copy-number, fusion-gene, and splice-variant expression 
calling was done using the Illumina Basespace sequence 
hub. Very deep sequencing was performed to enable quan-
tification of subclonal EGFR variants. All variants with a 
variant allele fraction (VAF) > 15% were included in the 
analysis, except for EGFR, where all VAFs were included as 
all variants in EGFR are subclonal. SNVs with quality scores 
<70 and/or present in the Exac database at fractions >0.001 
were omitted from the analysis. Splice variants/mutations 
were calculated as the “spliced-in fraction”; the number of 
mutant reads as fraction of the total reads over that partic-
ular variant. Data were further analyzed in R using ggplot2, 
survival, and GenVisR packages. Expression values were 
estimated using featureCounts using gencode-29 as gene 
Importance of the Study
Recurrent glioblastoma patients have a dismal 
prognosis; the median survival is ~6–8 months 
and there is no standard of care. Depatux-m is 
an antibody–drug conjugate with signs of clin-
ical activity in recurrent glioblastomas when 
given in combination with temozolomide. Here, 
we used material from a randomized phase II 
trial and identified patients that have survival 
benefit from this combination. We show that 
specific mutations increase sensitivity to EGFR 
ligands and this “hypersensitivity” can explain 
the observed treatment benefit. Our results in-
dicate that ligand hypersensitivity and ligand 
independence are two, inversely correlated, 
mechanisms to increase EGFR signaling. We 
also identified tumors harboring mutations 
sensitive to “classical” EGFR tyrosine-kinase 
inhibitors, providing a potential alternative 
treatment strategy. These data can help guide 
treatment for recurrent glioblastoma patients.





















annotation. One sample yielding only 707 reads was ex-
cluded from further analysis.
Whole transcriptome sequencing of rRNA depleted cDNA 
was done on the same isolate by GenomeScan (Leiden, 
The Netherlands) at a depth of 50 million paired-end reads 
per sample. HTStream was used to remove duplicate 
reads, fastp for low base quality trimming and adaptor re-
moval and further quality assessment. Alignment to hg38 
was done using STAR (2.6.1d). Stranded read-counts were 
estimated with STARs builtin “--quantMode GeneCounts” 
option. Samples with read-count <750,000 were excluded 
from further analysis (29 samples). DESeq2 was used for 
expression analysis and its VST-normalization for survival 
analysis using Coxph regression in R.
Data Analysis
For generating the waterfall plot of chromosomal changes, 
we defined trisomy as whole chromosome copy-number 
> 2.4 and LOH as copy-number < 1.6. For generating the 
waterfall plot per gene, we set a threshold for high-copy 
amplification to > 6 copies per cell, copy number gain (in-
cluding trisomy) between 3 and 6, and deep (homozygous) 
deletions at <1 copy per cell. All analyses to define variants 
associated with survival were done on samples with high 
copy amplification of EGFR only; samples without such 
high-level amplification may represent a different molec-
ular entity.
Constructs and Image Analysis
EGFR mutation constructs were generated by in-fusion 
cloning into a piggybac vector (System Biosciences, Palo 
Alto, CA) with eGFP cloned 3′ to the transmembrane do-
main as described.14 This position was chosen to avoid 
potential interference with ligand binding or receptor inter-
nalization–signaling sites. These constructs retain the im-
portant physical properties of EGFR with respect to signal 
transduction and protein–protein interactions.14 Stable 
HeLa cell-lines (ATCC, Manassas, VA) were created for all 
constructs. Cells were plated in 96 or 384 well plates for fur-
ther analysis. Following transfection, we selected for cells 
that expressed the (mutant) EGF receptor using FACS. As 
we did not select for a single cell clone, levels of EGFR ex-
pression were variable between individual cells. This way 
the observed responses can be evaluated across a wide 
range of expression levels. Quantification of EGFR sig-
nals intensities shows a high correlation between intensity 
and mRNA expression levels. This was done by comparing 
mRNA expression with signal intensities in various lung-
cancer cell lines (manuscript in preparation). Using this 
approach we show that the various mutation constructs 
had expression levels comparable to the endogenous 
EGFR expression in these cells (except for the cell lines ex-
pressing the EGFR_A289D or EGFRvIII mutation, where the 
construct is expressed at slightly lower levels; for EGFRvIII 
this was despite repeated attempts). Moreover, expression 
levels were highly similar between the various mutation 
constructs, again except for the cell line expressing the 
EGFR_A289D or EGFRvIII mutation.
All images were obtained using an Opera Phenix high-
throughput high-content confocal microscope (Perkin 
Elmer, Hamburg, Germany). At least 10 images were 
obtained per well so that hundreds of individual cells per 
condition were analyzed ensuring robustness of meas-
urements. Image analysis was performed using Harmony 
software (Perkin Elmer) using identical settings for all con-
ditions within each experiment and further analyzed using 
R.  Experiments were performed at least in three inde-
pendent replicates.
EGFR antibody (clone H11, DAKO, Amstelveen, The 
Netherlands) and a phospho-specific EGFR antibody 
(AB32430, anti phospho Y1068, Abcam, Cambridge, UK) 
were used at 1:500 dilution. Secondary antibodies used 
were alexafluor 647 goat anti-mouse, alexafluor 594 rabbit 
anti-mouse and alexafluor 488 goat anti-rabbit (A21240, 
A11062, and A11008, respectively, Invitrogen, Bleiswijk, The 
Netherlands). Hoechst was used as counterstain to visu-
alize nuclei.
Statistical Analysis
Distribution of frequencies was compared between sub-
types using the chi-squared test. A  Fisher’s exact test 
was used in case the assumptions for chi-square distri-
bution were violated as indicated in the respective ta-
bles. Kaplan–Meier survival curves were generated using 
the survival package in R.15 Overall survival was used to 
identify the molecular markers associated with outcome, 
with survival defined from the point of randomization until 
the date of death. If unavailable, the date of day known to 
be alive was used. The significance of prognostic factors 
was determined using Cox regression in univariate anal-
ysis. Differential gene expression was determined using 
de DESeq2 bioconductor package. P values less than .05, 
which were adjusted for a false discovery rate <0.05, were 
considered significant.
Results
Mutational Landscape of INTELLANCE-2/
EORTC_1410 Trial Samples
We first analyzed the molecular characteristics of tumors 
from patients included in the INTELLANCE-2/EORTC_1410 
trial. This is important as this allows defining the genomic 
landscape in tumors of patients that are eligible for clinical 
trial inclusion. Glioblastomas often have trisomy of chro-
mosome 7 and loss of chromosome 10 and, of the large 
scale genomic changes, these were indeed the two most 
commonly found (204 and 184 samples for chromosome 
7 and 10, respectively, Figure  1A). Combined trisomy 7, 
LOH 10 was observed in 176 of 236 samples (75%). Other 
common large chromosomal changes included gain of 
chromosomes 19 and 20 which are also frequently ob-
served in glioblastomas.
On the gene level, most, but not all, samples harbored 
high copy amplification of the EGFR locus (copy number 
> 6 in 200 tumors16); this was mainly observed in tumors 
with trisomy 7 (166/200, Figure  1B). Other high copy 
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amplified genes included MDM2 (n = 20), MDM4 (n = 21), 
CDK4 (n = 24), and CDK6 (n = 4). Most samples also har-
bored a homozygous deletion of the CDKN2A locus, and 
a small population had such deletions in the PTEN locus.
Mutations were identified in driver genes common 
to GBMs and included EGFR (n  =  115), PTEN (n  =  62), 
TP53 (n  =  48), CREBBP (n  =  21), and PIK3CA (n  =  16) 
















































































Figure 1. Genomic landscape of samples included in the INTELLANCE-2/EORTC_1410 trial. Shown are waterfall plots of chromosomal changes 
(A), gains and losses of individual genes (B), and SNVs within individual genes (C). The copy number changes, gene amplifications/deletions, and 
mutations are similar to observed in other (EGFR-amplified) glioblastoma datasets. Patients included in this study therefore were not selected for 
a specific molecularly subtype. LOH = loss of heterozygosity; HD = homozygous deletion.
  





















(Supplementary Figure 1), PTEN (see below), and EGFR. As 
may be expected, truncating mutations were common to 
tumor suppressor genes (PTEN, RB1, and NF1).
Common missense mutations identified in EGFR clus-
tered on the extracellular domain of the protein and in-
cluded R108, A289, and G598. Interestingly, we identified a 
new hotspot at the 3′ (intracellular) end of the gene where 
truncating mutations tended to cluster (Figure  2A). Such 
mutations often involved amino acids L1001 and M1002. 
We also identified three mutations in EGFR that, in lung 
cancer, are associated with response to EGFR tyrosine-
kinase inhibitors (TKIs).17 These mutations, G719A, G719D 
and S786I (~1.3% of analyzed samples), were present at a 
relatively high mutant allele fraction (in two samples, the 
variant allele fraction, VAF, exceeded >20%). Since the type 
of mutation may predict response to EGFR TKIs, such in-
hibitors may provide a new treatment option for these 
patients.18–20
The most common (oncogenic) splice variant identi-
fied was the glioblastoma-specific in-frame deletion of 
exons 2–7 (EGFRvIII), present in approximately half of all 
EGFR-amplified samples (n = 101, Figure 2B). Other vari-
ants present at significant population frequency included 
deletions of exons 9–10 (n  =  14), exons 25–26 (n  =  14), 
and exons 25–27 (n = 22), the latter two affecting the in-
tracellular domain. EGFR fusion genes were identified in 
13 samples, with fusion partners often located in the vi-
cinity of the EGFR gene locus (SEPT14, SEC61G, LANCL2). 
Similar to previously reported for glioblastomas, the mu-
tations, splice variants, and fusion genes identified in 
EGFR were almost always subclonal and many samples 
harbored more than one genetic change (Figure 2B).1 Only 
13/200 EGFR-amplified samples did not harbor any genetic 
change in the EGFR locus.
A289 Missense Mutations and 3′ Truncating 
Mutations in EGFR Are Associated With 
Response to Depatux-m + TMZ
We performed correlative analysis on genetic changes to 
identify those associated with survival in the depatux-m 
+ TMZ arm. Interestingly, the presence of SNVs (any pro-
tein altering SNV within the coding region) in EGFR was 
associated with survival in univariate analysis: the HR was 
0.495 with 95% CI [0.283, 0.865], P = .014 in the combina-
tion arm and 0.751, 95% CI [0.444, 1.272], P = 0.287 in the 
depatux-m monotherapy arm, compared with the CCNU or 
TMZ control arm (Table 1, Figure 3). Multivariable analysis 
confirmed that depatux-m + TMZ treatment was associated 
with survival in samples with EGFR-SNVs, independent 
of known prognostic factors such as age and MGMT pro-
moter methylation status (HR 0.45, 95% CI [0.26, 0.76], 
P = 0.003; Supplementary Table 1). No such association was 
found in the samples without EGFR-SNVs (HR 0.85, 95% CI 
[0.48, 1.50], P =  .57). Since depatux-m specifically targets 
EGFR, we focused further on individual variants to deter-
mine which of these were most associated with survival. 
A  trend was observed in tumors harboring A289 hotspot 
mutations (HR 0.386, 95% CI [0.138, 1.082], P = .070, Table 1, 
Figure 4A). No other individual SNV reached such statis-
tical values, but this may be related to the low number of 
samples harboring individual SNVs and the corresponding 
limited statistical power.
On the splice variant level, we found that a deletion of 
exons 25–27, affecting the C-terminal intracellular domain, 
was also associated with survival in the depatux-m + TMZ 
arm. Although there are relatively few samples (n = 22) with 
this genetic change, the HR was 0.255 with 95% CI [0.077, 
0.846] and P = .026 (Table 1, Figure 5). The ∆ex 25–27 splice 
variants introduce a frame shift in exon 28 resulting in a 
deletion of the C-terminal tail (exons 25–28) of EGFR. We 
therefore included C-terminal truncating mutations (SNVs 
leading to frameshifts and premature termination codons 
and fusion genes at the 3′ end of the gene) in this analysis 
and found that the association remained significant (HR 
0.175, 95% CI [0.054, 0.574], P = .004 for the combination 
of depatux-m +TMZ). The association also remained signif-
icant when other 3′ mutations were included in the anal-
ysis: 3′ end missense mutations (n = 10) center around two 
hotspots at amino acids 993–1014 and 1065–1070 and it is 
possible that they affect a functional domain similar to the 
domain lost in the truncating mutations (Table 1, Figure 5). 
Exon deletions overlapping the hotspots ∆ex 25–26 or ∆ex 
27, identified in 14 and 5 samples, respectively, may af-
fect a similar domain. When all C-terminal mutations were 
combined (∆ex 25–28, ∆ex 25–26, ∆ex 27, protein trunca-
tion SNVs, and/or other 3’SNVs fusion genes, n = 28 sam-
ples), the HR for depatux-m + TMZ was 0.309 [0.130, 0.735], 
P  =  .008. Depatux-m monotherapy was not significantly 
associated with survival (HR 0.514 [0.229, 1.155], P = .107, 
Table  1, Figure  5). We acknowledge that care should be 
taken when conducting such post hoc and combinatorial 
analyses, therefore, the analysis of each variant type is 
listed separately (Table 1).
Expression of EGFRvIII is common in glioblastomas and, 
since depatux-m also has affinity for this deletion variant, 
we were particularly interested in association with sur-
vival. In contrast to what might be expected, the absence 
of EGFRvIII expression showed a trend towards associa-
tion with survival: the HR was 0.582, 95% CI [0.311, 1.088], 
P = .090 in the combination arm and 1.004, 95% CI [0.570, 
1.771], P =  .988 in the depatux-m monotherapy arm both 
compared with the CCNU or TMZ control arm (Table  1, 
Figure  3, all treatment arms shown in Supplementary 
Figure 2). Multivariable analysis including MGMT pro-
moter methylation status and age confirmed the trend 
towards association of depatux-m + TMZ with survival in 
samples without EGFRvIII expression-SNVs (HR 0.57, 95% 
CI [0.31, 1.03], P = .064, Supplementary Table 1).
Because MGMT status is predictive for response to TMZ 
chemotherapy, we stratified the molecular markers asso-
ciated with survival (EGFR-SNVs and absent EGFRvIII ex-
pression) by this factor. Although sample size is relatively 
small, both depatux-m + TMZ and MGMT promoter meth-
ylation status were associated with improved outcome and 
both associations remained significant in a multivariable 
analysis containing both factors (Supplementary Figure 3).
Extracellular Missense Mutations Result in a 
Receptor With Increased Ligand Sensitivity
We next aimed to determine why SNVs in EGFR are associ-
ated with response to depatux-m + TMZ. First, the presence 
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Amino acid position 
Figure 2. Genetic changes within the EGFR gene of samples from patients included in the INTELLANCE-2/EORTC_1410 trial. (A) Lolliplot of SNVs 
identified showing characteristic hotspot mutations in the extracellular domain. (B) Waterfall plots of genetic changes subdivided in copy number 
gains, splice variant expression, and mutations. The waterfall plot is color coded to represent the level of copy number gain (in the CNV plot) or 



















































Table 1. Genetic changes in EGFR and other genes associated with response to depatux-m + TMZ
EGFR mutation/Gene Treatment HR 95% CI Pr(>|z|) n events survival (months)
Any mutation TMZ|CCNU     28 26 6.8
 depatux-m 0.751 0.444 1.272 0.287 37 31 8.4
 TMZ+depatux-m 0.495 0.283 0.865 0.014 33 26 11.7
Hotspot mutation TMZ|CCNU     15 14 7.1
 depatux-m 1.058 0.530 2.113 0.873 21 20 7.0
 TMZ+depatux-m 0.510 0.247 1.055 0.070 21 16 10.5
 A289 TMZ|CCNU     8 8 7.5
 depatux-m 0.799 0.313 2.037 0.638 11 11 6.2
 TMZ+depatux-m 0.386 0.138 1.082 0.070 11 8 10.4
 G598 TMZ|CCNU     4 4 4.2
 depatux-m     1 0 NA
 TMZ+depatux-m 0.254 0.027 2.370 0.229 2 1 7.8
 R108 TMZ|CCNU     3 2 5.2
 depatux-m 1.814 0.325 10.120 0.497 5 5 7.8
 TMZ+depatux-m 1.076 0.207 5.590 0.931 6 6 9.3
EGFRvIII absent TMZ|CCNU     22 20 9.1
 depatux-m 1.004 0.570 1.771 0.988 35 30 7.9
 TMZ+depatux-m 0.582 0.311 1.088 0.090 28 21 14.1
EGFRvIII present TMZ|CCNU     43 40 7.5
 depatux-m 0.894 0.553 1.446 0.649 33 29 7.3
 TMZ+depatux-m 0.673 0.412 1.099 0.114 33 27 9.8
 ∆ex25-27 TMZ|CCNU     11 11 5.1
 depatux-m 0.285 0.087 0.937 0.039 6 5 9.4
 TMZ+depatux-m 0.255 0.077 0.846 0.026 5 4 16.9
 ∆ex25-26 TMZ|CCNU     5 3 8.4
 depatux-m 1.691 0.399 7.166 0.476 6 5 5.5
 TMZ+depatux-m 0.629 0.104 3.804 0.614 3 2 14.4
 ∆ex27 TMZ|CCNU     2 2 6.6
 depatux-m 2.145 0.117 39.265 0.607 1 1 3.9
 TMZ+depatux-m 0.351 0.031 3.978 0.398 2 2 14.1
 C-term del TMZ|CCNU     2 2 6.8
 depatux-m 1.414 0.085 23.570 0.809 1 1 3.5
 TMZ+depatux-m 0.000 0.000 Inf 0.999 3 1 NA
















































EGFR mutation/Gene Treatment HR 95% CI Pr(>|z|) n events survival (months)
 depatux-m 0.107 0.009 1.278 0.077 4 2 17.8
 TMZ+depatux-m 0.077 0.005 1.192 0.067 3 1 NA
 all-C-term TMZ|CCNU     16 14 5.1
 depatux-m 0.514 0.229 1.155 0.107 15 12 8.5
 TMZ+depatux-m 0.309 0.130 0.735 0.008 13 9 16.9
 all C-term trunc TMZ|CCNU     13 13 5.1
 depatux-m 0.480 0.181 1.271 0.140 8 7 8.8
 TMZ+depatux-m 0.175 0.054 0.574 0.004 7 4 18.3
         
PTEN all TMZ|CCNU     16 16 8.4
 depatux-m 0.692 0.353 1.353 0.282 23 19 8.4
 TMZ+depatux-m 0.499 0.241 1.034 0.061 20 15 10.2
PTEN HD TMZ|CCNU     14 13 5.4
 depatux-m 1.291 0.540 3.088 0.566 9 9 5.5
 TMZ+depatux-m 0.392 0.125 1.229 0.108 7 6 8.2
PTEN SNV TMZ|CCNU     13 13 8.8
 depatux-m 0.876 0.636 1.207 0.417 18 15 8.7
 TMZ+depatux-m 0.659 0.475 0.914 0.013 15 11 11.0
ARID1A SNV TMZ|CCNU     2 2 2.6
 depatux-m 0.541 0.086 3.410 0.513 5 5 5.4
 TMZ+depatux-m 0.139 0.015 1.258 0.079 5 3 16.6
ARID1A LOH TMZ|CCNU     3 3 10.5
 depatux-m     1 0 NA
 TMZ+depatux-m 0.286 0.047 1.745 0.175 6 5 15.1
AIRD1A SNV+LOH TMZ|CCNU     5 5 4.2
 depatux-m 0.572 0.158 2.070 0.395 6 5 8.2
 TMZ+depatux-m 0.269 0.075 0.961 0.043 11 8 15.4
RP11.770J1.4 TMZ|CCNU     10 10 6.7
 depatux-m 0.831 0.379 1.821 0.643 19 17 8.4
 TMZ+depatux-m 0.322 0.100 1.036 0.057 8 4 14.8
DHFR TMZ|CCNU     28 27 9.5
 depatux-m 1.003 0.599 1.677 0.992 36 32 7.9
 TMZ+depatux-m 0.587 0.345 1.001 0.050 36 28 11.7
OS = Median overall survival. Hotspot mutations are defined as amino acid changes present in at least four samples and involve amino acids, A289, G598, R222, R108, K261, P266, H304, H773, V774, and/or M1002.
  





















of SNVs and absence of EGFRvIII expression identify a 
similar population: the majority of samples expressing 
EGFRvIII do not express additional EGFR mutation vari-
ants (18/96) and the majority of samples harboring SNVs 
do not express EGFRvIII (18/57), P = .004 (chi-square test, 
Figure 3C). The level of EGFRvIII expression is also lower 
in samples expressing SNVs: The spliced-in fraction (the 
number of mutant reads as fraction of the total EGFR 
reads) was 0.12 ± 0.22 vs. 0.29 ± 0.36, P < .001. Conversely, 
the level of EGFR SNVs was lower in samples expressing 
EGFRvIII compared with those that do not express EGFRvIII 
(spliced-in fraction, calculated only using reads covering 
the affected base, was 0.11 ± 0.22 vs. 0.35 ± 0.38, P < .001). 
The difference in expression is even larger when only fo-
cusing on hotspot mutations (i.e., any mutation occurring 
in at least four samples) where the spliced in fraction of 
EGFRvIII was 0.09 ± 0.18 vs. 0.45 ± 0.33 in mutation positive 
v negative tumors (P < .001). The inverse correlation be-
tween expression of EGFRvIII and SNVs was not specific to 
samples included in this study; glioblastoma samples in-
cluded in the randomized phase II BELOB trial and in TCGA 
samples show a near identical and statistically significant 
inverse correlation (Supplementary Figure 4).1,21 This in-
verse correlation suggests a divergent evolution where, 
after the initial amplification of EGFR, glioblastomas de-
velop either EGFRvIII or other EGFR mutations.
To understand why SNVs in EGFR are associated with 
survival in the depatux-m + TMZ arm, we performed func-
tional analysis on various EGFR-mutation constructs. The 
majority of hotspot mutations in glioblastomas are local-
ized in the extracellular, ligand binding domain of EGFR, 
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Figure 3. Genetic changes within the EGFR gene that were associated with prolonged survival with depatux-m + TMZ. (A) Presence of SNVs; (B) 
absence of EGFRvIII expression. Hazard rates of these changes are listed in Table 1. Both genetic changes are correlated as samples containing 
SNVs often do not express EGFRvIII and vice versa (C).
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Figure 4. (A) A289x hotspot mutations are associated with response to depatux-m + TMZ. (B) Example of microscopic images of EGFR-wt and 
EGFRR108K stimulated with either EGF or AREG. Green: EGFR, red: phospho-EGFR, blue: Hoechst. AREG resulted in increased receptor endocy-
tosis and phospho-EGFR signal in EGFRR108K compared to EGFR-wt. (C) Example of analysis depicting the level of phospho-EGFR (y-axis) against 
total EGFR (x-axis) within individual EGFR positive vesicles. Each dot represents one EGFR-positive submenbranous vesicle. (D) Averages of 
experiments plotted in (C). (E) Similar to (B) the level of phospho-EGFR (y-axis) is plotted against total EGFR (x-axis) within individual EGFR pos-
itive vesicles. As can be seen, apart from EGFRvIII, all constructs responded, dose dependently, to the high affinity ligands EGF, HB-EGF, TGFA, 
and BTC by an increase in EGFR phosphorylation. Low affinity ligands AREG, EREG, and EPGN were not able to stimulate EGFR-wt constructs, 
but resulted in a strong activation of extracellular domain mutations EGFRR108K, EGFRA289V, and EGFRG598V. The absence of responses in EGFRvIII-
expressing cells is in line with the notion that this mutation is independent of ligand. Images were taken at 40× magnification.
  





















activation. We therefore stimulated various mutation con-
structs with two different EGFR ligands: one high affinity 
ligand (EGF) and one low affinity ligand (Amphiregulin, 
AREG). Stimulation with 200 ng/ml EGF resulted in a strong 
increase EGFR-phosphorylation in all constructs (except 
for EGFRvIII; this constitutively active variant is ligand in-
dependent22,23) (Figure 4). In contrast, the low affinity EGFR 
ligand amphiregulin (AREG, 200  ng/ml) only marginally 
activated the control constructs EGFR-wt and EGFRV834L 
and did not activate EGFRvIII. Interestingly, AREG stimu-
lation had a strong effect on all constructs harboring ex-
tracellular missense mutations found in glioblastomas 
(EGFRR108K, EGFRG598V, and EGFRA289V). AREG activated 
these EGFR-mutation constructs at levels 40%–80% of that 
observed by EGF stimulation, a 3-8 fold increase compared 
with EGFRwt constructs (P < .02 for any extracellular mu-
tation construct vs. EGFRwt and P < .05 for any of the ex-
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Figure 5. C-terminal truncating mutations are associated with response to depatux-m + TMZ. Deletion of exons 25–27 results in a frame shift of 
the protein. Such changes are associated with response to depatux-m + TMZ (top right). Nonsense and frameshift mutations show a similar trend 
(middle panels, left lolliplot of individual mutations, right survival analysis), as do the C-terminal SNVs (bottom panels, left lolliplot of individual mu-
tations, right survival analysis). Hazard rates of individual changes are listed in Table 1.
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Mutations commonly found in lung cancer (EGFRL858R and 
EGFRA746-E750del) responded to EGF and AREG similar to the 
control constructs.
To determine whether extracellular domain mutations 
were also more sensitive to other EGFR ligands, we tested 
all seven known ligands for EGFR activation. For each li-
gand, we performed a dose–response analysis ranging 
from 200  ng/ml (maximal stimulation) to 0.8  ng/ml. In 
the control constructs, all high affinity EGFR ligands (EGF, 
TGFα, HB-EGF, and BTC) resulted in a strong activation and 
all low affinity ligands AREG, EREG, and EPGN resulted 
in a markedly weaker activation (Figure 6). In contrast, 
however, all extracellular missense mutations, EGFRA298V, 
EGFRG598V, and EGFRR108K, showed strong activation to-
wards all EGFR ligands, including the low affinity ligands 
AREG, EPGN, and EREG (Figure 6). EGFRvIII did not re-
spond to any of the ligands. These experiments therefore 
show that EGFR containing extracellular missense muta-
tions render the receptor more sensitive to stimulation, 
especially by the weak activators AREG, EREG, and EPGN.
The hypersensitivity of extracellular domain mutations 
may explain the increased responsiveness to depatux-m: 
receptors are more easily activated and, as activation leads 
to receptor internalization, increased internalization with 
the antibody/drug conjugate. Hypersensitivity likely also 
leads to an increased exposure of the epitope for the anti-
body (i.e., the activated conformation of EGFR).24
Our molecular imaging analysis also showed that 
EGFRvIII mainly has an intracellular localization 
(Supplementary Figure 5). This is in contrast to control con-
structs which are mainly localized to the membrane. Other 
activating mutations such as EGFRL858R also showed a cer-
tain degree of increased intracellular localization, but only 
EGFRvIII showed such prominent intracellular localization. 
The increased responsiveness in samples without EGFRvIII 
expression therefore can be explained by the near absence 
of EGFRvIII on the extracellular membrane: this may pre-
vent effective binding to depatux-m.
Functional analysis indeed confirmed the direct correla-
tion between receptor internalization and EGFR antibody 
internalization: EGFR receptor internalization still occurred 
in the presence of either ABT806 or cetuximab, regardless 
of ligand or mutation present, whereas this internalization 
could be completely inhibited by erlotinib or lapatinib (re-
spectively, type I  and II TKIs). The internalization was ac-
companied by uptake of EGFR antibodies as demonstrated 
by staining cells only with secondary antibodies directed at 
the FC fragment (Supplementary Figure 6).
Additional Genetic Events Associated With 
Survival in the Depatux-m + TMZ Arm
We also performed correlative analysis to screen for other 
events associated with patient survival in the depatux-m + 
TMZ arm. We focused on genetic events (SNVs and CNVs) 
present in at least nine samples and selected those showing 
a trend (P < .10) by Cox regression analysis. Of the 149 genes 
examined, inactivating PTEN mutations were associated 
with outcome to depatux-m + TMZ; the HR was 0.499 with 
95% CI [0.241, 1.034], P = .061 (Table 1, Supplementary Figure 
7). For this analysis, we combined samples with homozygous 
deletion and SNVs (individual mutation types showed a sim-
ilar trend, Table  1). Combining homozygous deletion with 
SNVs was warranted as many of the SNVs in PTEN led to 
premature stop codons and most of the missense mutations 
are listed in the COSMIC database25 with high pathogenic 
prediction scores (FATHMM26) (Supplementary Table 2).
A second gene associated with survival was ARID1A, a 
tumor suppressor gene that is mutated in various cancer 
types including ovarian, endometrial, and uterine cancer.27 
Mutations in this gene are often heterozygous which sug-
gests that inactivation of one allele is sufficient to relieve 
the tumor suppressive effect of the protein.27 The identi-
fied SNVs in ARID1A in our samples were also heterozy-
gous. When combining samples with ARID1A LOH (n = 10) 
and missense mutations (n  =  12), the HR for depatux-m 
+ TMZ was 0.27 (95% CI [0.074, 0.961], P  =  .04) (Table  1, 
Supplementary Figure 8; analysis of LOH and SNVs indi-
vidually is also listed). SNVs in dihydro-folate reductase 
(DHFR, a gene required for the de novo synthesis of pur-
ines) and RP11.770J1.4 (a long intragenic noncoding RNA) 
were also associated with response to the combination of 
depatux-m + TMZ (HR 0.587, P = .050 and HR 0.322, P = .057, 
respectively, Supplementary Figure 8).
Because inactivating alterations in PTEN and TP53 are 
associated with EGFR kinase inhibitor response in sev-
eral cancer types (see, e.g., ref. 28), we performed a mul-
tivariate analysis including these genes and show that 
depatux-m + TMZ remained a factor associated with sur-
vival (Supplementary Table 3).
Gene Expression Analysis
Whole transcriptomic analysis identified genes associ-
ated with survival in each of the three treatment arms 
(Supplementary Tables 4–6). For each of these gene-lists, 
several genes were co-expressed which is suggestive for 
higher-order interactions (Supplementary Figure 9). Gene-
set enrichment analysis identified various pathways asso-
ciated with survival including “cell cycle,” “cell activation,” 
and “meiotic cell cycle process,” and various pathways 
associated with immune response including “immune 
system development” and “lymphocyte activation.” We did 
not find a correlation between the level of immune infil-
tration and survival as determined by Immunophenoscore 
analysis.29 One gene, N-MYC downstream regulated gene 
2 (NDRG2), was specifically associated with survival in the 
depatux-m + TMZ arm and not in the other two arms of the 
study (Supplementary Figure 9), suggesting that this gene 
is predictive for response to the combination treatment. 
Other studies have also shown similar correlation between 
expression and survival of NDRG2 in glioblastomas.30
The survival curves in both depatux-m treated arms 
show a tail suggesting more long survivors (>365  days 
from randomization) when treated with the drug. Gene ex-
pression analysis between long and short survivors identi-
fied 15 differentially expressed genes, including CDK4 and 
6 genes that neighbor it. We find approximately 2.2 times 
more CDK4-amplified samples in patients with survival < 
365 days (P =  .004, see also ref. 31). Expression of FOXF1 
was significantly higher in short- compared with long sur-
vivors (P = .010, Supplementary Figure 10).






















In this study, we have performed detailed molecular ana-
lyses on glioblastomas of patients treated within the 
INTELLANCE-2/EORTC_1410 randomized phase II clinical 
trial. Our results suggest that patients harboring tumors 
with EGFR SNVs may derive more benefit from the combi-
nation of depatux-m + TMZ.
Three mechanisms can explain the survival benefit of 
these variants to depatux-m + TMZ. First, we show that 
extracellular domain mutations result in a receptor that is 
hypersensitive to activation by the various EGFR ligands. 
Since EGFR is internalized after receptor activation,32 the 
hypersensitivity likely increases internalization and so 
increase uptake of the antibody–drug conjugate. Second, 
hypersensitive mutations increase transformation towards 
the active conformation of the protein. EGFR can switch 
between inactive (closed) and active (domain II exposed) 
conformation; the presence of ligand locks the protein in 
the active conformation.20,33 Hypersensitive mutations 
may shift the equilibrium towards the active conformation 
of the protein. Indeed, such mutations have been demon-
strated to increase exposure of the epitope for the ABT806 
antibody, and so result in increased binding of depatux-m.24 
Thirdly, we show that EGFRvIII expression is inversely cor-
related with the presence of SNVs in EGFR. Since EGFRvIII 
mainly has an intracellular localization (see also ref. 34), its 
near absence on the extracellular membrane may prevent 
binding to depatux-m, samples without EGFRvIII expres-
sion (i.e., predominantly those with EGFR SNVs) are more 
likely to respond to depatux-m. Other mechanisms, how-
ever, may also determine sensitivity/resistance.35
Our results are in line with two recent publications 
both using mice engrafted with cell lines specifically 
overexpressing either EGFRA289V or EGFRG598V ECD mu-
tations. Both studies showed significant survival benefit 
from treatment with ABT806 (i.e., the antibody used in 
depatux-m).24,36 Since our study also suggested benefit 
when such mutations are present, and given the mecha-
nistic insight of its possible mode of action, further inves-
tigation into the efficacy of depatux-m in glioblastoma 
patients with ECD mutations is warranted.
We also show that intracellular EGFR truncating muta-
tions and splice variants are associated with response to 
depatux-m + TMZ. Other studies have shown that such 
truncating mutations result in altered receptor internali-
zation37,38 and this altered internalization therefore may be 
linked to treatment response and survival benefit. Similarly, 
bi-allelic inactivation of PTEN also was associated with re-
sponse to depatux-m + TMZ. Since poly-phosphoinositides 
are key regulators of membrane trafficking, they also may 
contribute to altered receptor endocysis. PtdIns(4,5)P2, for 
example, is required in the progression of early endocy-
tosis39 and PtdIns(4,5)P2 is produced from PTEN substrate 
PtdIns(3,4,5)P3.
One important caveat of this study is that the correlative 
analysis are post hoc, and therefore, these observations 
require confirmation in an independent dataset: our anal-
ysis may have incorrectly identified markers associated 
with survival in the depatux-m + TMZ arm due to multiple 
testing. Such dataset may be available in the INTELLANCE-1 
trial that examined the effect of depatux-m in combination 
with chemoradiation compared with chemoradiation only 
in newly diagnosed glioblastoma patients (clinicaltrials.
gov identifier NCT02573324). Of note, this trial did not 
meet its primary endpoint, though trial results have not 
been published to date. The difference between the two 
trials may lie in the fact that the patients treated within 
INTELLANCE-1 received surgery prior to treatment. The 
remaining tumor cells in INTELLANCE-1 therefore were 
likely in areas with an intact blood-brain barrier, which may 
have reduced accessibility to depatux-m. In addition, most 
of the samples analyzed in the current study were derived 
from primary tumors (in ~80% of cases) as surgery at re-
currence is seldom performed. Various changes can occur 
during tumor evolution and some specifically affect EGFR 
variants.40–42 EGFRvIII expression, for example, is often 
lost at tumor recurrence43–45; ~1/3 of EGFR-mutations are 
also lost at tumor recurrence.46 Nevertheless, the copy 
number changes, gene amplifications/deletions and muta-
tions are similar to observed in other (EGFR-amplified) gli-
oblastoma datasets, and therefore patients included in the 
INTELLANCE-2/EORTC_1410 trial did not select for a spe-
cific and molecularly defined tumor type.1 Another limita-
tion of our study is the that response is extrapolated from 
survival data. Correlation of response as seen on MRI with 
molecular features may identify different genetic markers.
Our data also provide a model for tumor evolution 
with respect to EGFR-dependency. GBMs require EGFR 
signaling for growth and EGFR amplification is the first step 
in GBMs to meet this requirement. After this initial ampli-
fication, the tumor evolves to facilitate the need for EGFR 
signaling by gaining additional and activation mutations. 
Our data show that there are at least two different modes 
of evolution in glioblastomas: by becoming independent of 
ligand (EGFRvIII) or by becoming hypersensitive to ligand 
(extracellular hotspot mutations). Since both EGFRvIII and 
extracellular domain mutations have tumorigenic proper-
ties,22,47,48 only one of these mutations is required to facil-
itate the need for EGFR signaling. This explains why, in all 
the glioblastoma datasets examined, EGFRvIII expression is 
inversely correlated with presence of EGFR-missense muta-
tions (Figure 3 and Supplementary Figure 4).
In addition to finding associations of specific EGFR 
variants associated with response to depatux-m + TMZ, 
we also found rare mutations that, in pulmonary adeno-
carcinoma patients, respond to EGFR-TKIs. Several lines 
of evidence suggest that responses to EGFR-TKIs are de-
pendent on the type of mutation and not on the type of 
tumor. For example, TKI-sensitive mutations in pulmonary 
adenocarcinomas are also sensitive to these TKIs in other 
tumor types.49–51 Such responses have also been docu-
mented for the mutations identified in this study.18,19 These 
TKI-sensitive mutations have been identified in other gli-
oblastoma datasets, and although present in only a small 
minority (~1–2%) of EGFR-amplified GBMs), EGFR-TKIs 
may prove an interesting treatment option for patients har-
boring such tumors. However, one complicating factor is 
that EGFR mutations in glioblastomas almost invariably are 
subclonal. In addition, they often show high intratumoral 
(and temporal) heterogeneity.46 It is therefore possible that 
EGFR-TKIs may only be effective in tumors with a high var-
iant allele fraction of the TKI-sensitive mutation.
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